Atea Pharmaceuticals, Inc.

AVIRSEC EDGAR

Pharmaceutical Preparations(MA)CIK: 1593899

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	$48.6M	$48.6M
Research and Development Expense	$144.1M	$114.2M	$81.9M	$38.0M	$10.2M
Operating Expenses	$192.9M	$164.2M	$130.7M	$59.7M	$14.6M
Operating Income (Loss)	-$192.9M	-$164.2M	-$130.7M	-$11.0M	-$14.6M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$167.5M	-$134.9M	-$119.5M	-$10.9M	-$14.0M
Income Tax Expense (Benefit)	$925.0K	$1.0M	-$3.6M	$17.4M	$17.4M
Net Income (Loss) Attributable to Parent	-$168.4M	-$136.0M	-$115.9M	-$10.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$464.7M	$595.0M	$666.7M	$772.9M	$863.6M
Assets, Current	$462.4M	$590.5M	$660.9M	$772.4M	$863.5M
Cash and Cash Equivalents, at Carrying Value	$64.7M	$143.8M	$188.5M	$850.1M	$21.7M
Liabilities	$25.8M	$39.8M	$26.1M	$62.8M	$315.8M
Liabilities, Current	$18.6M	$32.4M	$18.5M	$56.9M	$315.8M
Accounts Payable, Current	$4.5M	$4.3M	$2.6M	$4.5M	$60.0K
Stockholders' Equity Attributable to Parent	$555.2M	$640.6M	$710.1M	-$49.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$135.5M	-$85.4M	-$121.0M	$296.7M	-$12.8M
Net Cash Provided by (Used in) Investing Activities	$56.1M	$40.3M	-$455.4M	-$26.0K	-$2.0K
Net Cash Provided by (Used in) Financing Activities	$267.0K	$257.0K	$370.0K	$531.7M	$531.7M
Payments to Acquire Property, Plant, and Equipment	—	—	$1.9M	$26.0K	$2.0K
Payments for Repurchase of Common Stock	$0.00	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)